KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Operating Leases (2019 - 2025)

BeOne Medicines (ONC) has disclosed Operating Leases for 7 consecutive years, with $52.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases rose 19.57% to $52.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.9 million, a 19.57% increase, with the full-year FY2025 number at $52.9 million, up 19.57% from a year prior.
  • Operating Leases was $52.9 million for Q4 2025 at BeOne Medicines, up from $51.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $54.9 million in Q1 2025 to a low of $17.7 million in Q1 2024.
  • A 5-year average of $37.2 million and a median of $36.2 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 45.54% in 2024, then skyrocketed 209.76% in 2025.
  • BeOne Medicines' Operating Leases stood at $43.0 million in 2021, then decreased by 19.8% to $34.5 million in 2022, then tumbled by 35.54% to $22.3 million in 2023, then soared by 98.99% to $44.3 million in 2024, then grew by 19.57% to $52.9 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Operating Leases are $52.9 million (Q4 2025), $51.4 million (Q3 2025), and $53.9 million (Q2 2025).